News Eris Lifesciences Limited Bombay S.E.

Equities

540596

INE406M01024

Market Closed - Bombay S.E. Other stock markets 03:30:48 30/04/2024 pm IST			5-day change	1st Jan Change
891.6 ^INR	-0.34%		+0.91%	-2.09%

03/04	Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	MT
15/03	Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	03/04	MT
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	15/03	MT
Transcript : Eris Lifesciences Limited - Shareholder/Analyst Call	14/03
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	14/03	MT
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million	14/03	RE
Eris Lifesciences Limited agreed to acquire Biocon Biologics India Branded Formulations business for INR 12.42 billion.	14/03	CI
Eris Lifesciences Completes Purchase of 51% Stake in Swiss Parenterals	16/02	MT
Eris Lifesciences Limited completed the acquisition of 51% stake in Swiss Parenterals Limited.	15/02	CI
Eris Lifesciences Limited Provides Earnings Guidance for the Fiscal 2025 and Fiscal 2026	13/02	CI
Transcript : Eris Lifesciences Limited, Q3 2024 Earnings Call, Feb 13, 2024	13/02
Eris Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02	CI
Eris Lifesciences Limited agreed to acquire 51% stake in Swiss Parenterals Limited INR 6.4 billion.	13/02	CI
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns	08/02	RE
Eris Lifesciences Limited completed the acquisition of Dermatology and Nephrology branded formulations business units of Biocon Biologics	10/11	CI
Biocon Biologics Announces Divestment of Two Non-Core Branded Formulations, India Business Units	09/11	AQ
Indian shares set to open higher tracking Asian peers	09/11	RE
Eris Lifesciences Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024	08/11	CI
Transcript : Eris Lifesciences Limited, Q2 2024 Earnings Call, Nov 08, 2023	08/11
Eris Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	08/11	CI
Eris Lifesciences Limited entered into a definitive agreement to acquire Dermatology and Nephrology branded formulations business units of Biocon Biologics for INR 3.7 billion.	08/11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Eris Lifesciences Limited Bombay S.E.

Equities

540596

INE406M01024

Summary

Filters